Drug Trial Radar · NCT02517385
Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
Last checked: Nov 20, 2026Latest source record: Jul 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Aug 2015
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 66 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To assess safety of Phosphatidylcholine paste 600 mg (ESSENTIALE® paste) oral 3 times a day for 12 weeks in patients with gastrointestinal symptoms in acute and chronic liver diseases. Secondary Objectives: To assess effectiveness on symptomatic improvement in patients with gastrointestinal symptoms in acute and chronic liver diseases. To monitor compliance.
Conditions
- Hepatic and Hepatobiliary Disorders
Interventions
PhosphatidylcholineDrug
Pharmaceutical form:Paste Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency (number) of adverse events (AEs) related to the investigational drugTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.